Aviance Capital Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-989
| Closed | -$229K | – | 335 |
|
|
2024
Q2 | $229K | Buy |
989
+19
| +2% | +$4.13K | 0.03% | 293 |
|
|
2024
Q1 | $209K | Sell |
970
-60
| -6% | -$14.1K | 0.03% | 295 |
|
|
2023
Q4 | $267K | Sell |
1,030
-5
| -0.5% | -$1.23K | 0.06% | 212 |
|
|
2023
Q3 | $266K | Hold |
1,035
| – | – | 0.06% | 213 |
|
|
2023
Q2 | $295K | Sell |
1,035
-100
| -9% | -$29.8K | 0.06% | 215 |
|
|
2023
Q1 | $316K | Hold |
1,135
| – | – | 0.07% | 215 |
|
|
2022
Q4 | $314K | Sell |
1,135
-50
| -4% | -$14.1K | 0.07% | 215 |
|
|
2022
Q3 | $316K | Sell |
1,185
-197
| -14% | -$41.8K | 0.08% | 203 |
|
|
2022
Q2 | $282K | Sell |
1,382
-590
| -30% | -$121K | 0.06% | 224 |
|
|
2022
Q1 | $415K | Sell |
1,972
-78
| -4% | -$17K | 0.08% | 196 |
|
|
2021
Q4 | $492K | Sell |
2,050
-8,849
| -81% | -$2.28M | 0.08% | 189 |
|
|
2021
Q3 | $3.08M | Buy |
10,899
+1,409
| +15% | +$462K | 0.54% | 45 |
|
|
2021
Q2 | $3.29M | Sell |
9,490
-2,870
| -23% | -$869K | 0.57% | 42 |
|
|
2021
Q1 | $3.46M | Buy |
12,360
+49
| +0.4% | +$13.2K | 0.67% | 41 |
|
|
2020
Q4 | $3.01M | Sell |
12,311
-715
| -5% | -$184K | 0.61% | 41 |
|
|
2020
Q3 | $3.69M | Buy |
13,026
+558
| +4% | +$156K | 0.83% | 28 |
|
|
2020
Q2 | $3.34M | Buy |
12,468
+396
| +3% | +$119K | 0.82% | 26 |
|
|
2020
Q1 | $3.82M | Buy |
12,072
+893
| +8% | +$271K | 1.2% | 14 |
|
|
2019
Q4 | $3.32M | Sell |
11,179
-4
| -0% | -$1.11K | 0.85% | 21 |
|
|
2019
Q3 | $2.6M | Buy |
11,183
+5,229
| +88% | +$1.22M | 0.77% | 29 |
|
|
2019
Q2 | $1.39M | Sell |
5,954
-452
| -7% | -$104K | 0.38% | 79 |
|
|
2019
Q1 | $1.51M | Buy |
6,406
+556
| +10% | +$175K | 0.43% | 55 |
|
|
2018
Q4 | $1.76M | Sell |
5,850
-1,128
| -16% | -$360K | 0.62% | 38 |
|
|
2018
Q3 | $2.46M | Buy |
6,978
+100
| +1% | +$34.4K | 0.6% | 32 |
|
|
2018
Q2 | $2M | Buy |
6,878
+3,040
| +79% | +$855K | 0.58% | 39 |
|
|
2018
Q1 | $1.05M | Buy |
3,838
+229
| +6% | +$71.1K | 0.32% | 85 |
|
|
2017
Q4 | $1.15M | Sell |
3,609
-142
| -4% | -$45.6K | 0.38% | 72 |
|
|
2017
Q3 | $1.18M | Sell |
3,751
-625
| -14% | -$185K | 0.4% | 68 |
|
|
2017
Q2 | $1.19M | Buy |
4,376
+1,106
| +34% | +$292K | 0.38% | 75 |
|
|
2017
Q1 | $894K | Buy |
3,270
+37
| +1% | +$10.5K | 0.33% | 95 |
|
|
2016
Q4 | $917K | Sell |
3,233
-961
| -23% | -$285K | 0.32% | 89 |
|
|
2016
Q3 | $1.31M | Buy |
4,194
+251
| +6% | +$74.3K | 0.46% | 60 |
|
|
2016
Q2 | $953K | Sell |
3,943
-314
| -7% | -$82.8K | 0.35% | 78 |
|
|
2016
Q1 | $1.11M | Sell |
4,257
-966
| -18% | -$255K | 0.39% | 69 |
|
|
2015
Q4 | $1.6M | Buy |
+5,223
| New | +$1.5M | 0.55% | 48 |
|
Other funds holding BIIB
Aviance Capital Partners's BIIB Position: Q3 2024 in Review
Aviance Capital Partners sold out of Biogen (BIIB) in Q3 2024, closing a stake of 989 shares — an estimated $229K sold.
Aviance Capital Partners first reported a position in BIIB in Q4 2015 and held it in 35 quarters. The position peaked at $3.82M in Q1 2020. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.
- Aviance Capital Partners reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
- Aviance Capital Partners sold 989 Biogen shares in Q3 2024, an estimated $229K.
- Aviance Capital Partners first reported a position in Biogen in Q4 2015 and held it in 35 quarters.
- Aviance Capital Partners's Biogen position peaked at $3.82M in Q1 2020.
- 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.
Based on Aviance Capital Partners's 13F filing for Q3 2024, filed 7 Nov 2024.